Real-World Outcomes of Irinotecan-TACE for Colorectal Liver Metastases



The liver is the most frequent metastatic site in CRC, with 25% of patients presenting with CRLMs at diagnosis and 30%–50% developing them within 2 years. Transarterial chemoembolisation with irinotecan-eluting beads (irinotecan-TACE) provides a locoregional approach that delivers high-dose irinotecan to liver lesions while minimising systemic toxicity.

Copyright © 2020 Terumo India Private limited

X
Important information regarding

By using this website, you consent to the use of cookies in accordance with our